Alzamend Neuro, Inc. (ALZN)
1.66
-0.02
(-1.19%)
USD |
NASDAQ |
Sep 09, 10:55
Alzamend Neuro Enterprise Value : 6.439M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 6.439M |
| September 04, 2026 | 6.354M |
| September 03, 2026 | 6.524M |
| September 02, 2026 | 6.524M |
| September 01, 2026 | 6.256M |
| August 31, 2026 | 6.099M |
| August 28, 2026 | 6.354M |
| August 27, 2026 | 6.376M |
| August 26, 2026 | 6.397M |
| August 25, 2026 | 6.099M |
| August 24, 2026 | 5.886M |
| August 21, 2026 | 5.929M |
| August 20, 2026 | 6.227M |
| August 19, 2026 | 5.758M |
| August 18, 2026 | 5.758M |
| August 17, 2026 | 6.014M |
| August 14, 2026 | 5.886M |
| August 13, 2026 | 5.503M |
| August 12, 2026 | 5.418M |
| August 11, 2026 | 5.546M |
| August 10, 2026 | 5.503M |
| August 07, 2026 | 5.12M |
| August 06, 2026 | 5.163M |
| August 05, 2026 | 5.375M |
| August 04, 2026 | 5.460M |
| Date | Value |
|---|---|
| August 03, 2026 | 4.992M |
| July 31, 2026 | 4.865M |
| July 30, 2026 | 5.035M |
| July 29, 2026 | 4.992M |
| July 28, 2026 | 4.865M |
| July 27, 2026 | 4.992M |
| July 24, 2026 | 4.950M |
| July 23, 2026 | 4.652M |
| July 22, 2026 | 5.035M |
| July 21, 2026 | 4.907M |
| July 20, 2026 | 4.652M |
| July 17, 2026 | 4.439M |
| July 16, 2026 | 4.482M |
| July 15, 2026 | 4.524M |
| July 14, 2026 | 4.439M |
| July 13, 2026 | 4.226M |
| July 10, 2026 | 4.311M |
| July 09, 2026 | 4.226M |
| July 08, 2026 | 4.184M |
| July 07, 2026 | 4.141M |
| July 06, 2026 | 4.226M |
| July 02, 2026 | 4.226M |
| July 01, 2026 | 4.056M |
| June 30, 2026 | 4.396M |
| June 29, 2026 | 4.226M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.870M |
| Total Expenses (Quarterly) | 2.870M |
| EPS Diluted (Quarterly) | -0.7382 |
| Earnings Yield | -174.4% |
| Normalized Earnings Yield | -174.42 |